TheFly reported on April 13 that Mizuho reduced its price target on BSX to $90 from $115 while maintaining an Outperform ...

The device maker plans to invest 75 million euros into expanding the site, with a focus on cardiovascular innovation.

Wall Street analysts forecast that Boston Scientific (BSX) will report quarterly earnings of $0.80 per share in its upcoming release, pointing to a year-over-year increase of 6.7%. It is anticipated ...

Boston Scientific Corporation (NYSE:BSX) is included in our list of the best low-risk high-reward stocks. As part of the firm’s Q1 preview for medical technology and life science tools firms, Evercore ...

Technical indicators are flashing bullish for all three stocks.

Boston Scientific (NYSE:BSX) today announced a €75 million (approximately $88.4 million) investment at its Galway, Ireland, ...

Boston Scientific shared the results during a late-breaking presentation at this year’s EHRA congress in Paris, France.

The deal positions Boston Scientific to compete with Medtronic for a market that analysts believe is highly under-penetrated.

In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

On April 7, Joanne Wuensch from Citi reduced the price target on Boston Scientific Corp. (NYSE:BSX) from $98 to $87 while ...

Medical device manufacturer Boston Scientific has announced a €75m investment in its Galway site, including the expansion of its research and development (R&D) capabilities.

Galway's Boston Scientific is to advance its research and development capabilities, as well as therapies, with a €75m investment.